Timothy M. Shannon M.D. President and Chief Executive Officer
Dr. Shannon has served as President and Chief Executive Officer since September 2007, and was previously Executive Vice President of Research and Development and Chief Medical Officer at CuraGen since September 2002. Prior to joining CuraGen, Dr. Shannon served as Head and Senior Vice President of Global Medical Development at Bayer Pharmaceutical Group where he oversaw product development and portfolio management, from research through product registration, and held responsibility for all medical aspects of regulatory interaction, including successful FDA and EMEA/CPMP advisory hearings and audits. Dr. Shannon earned his B.A. in chemistry from Amherst College and his M.D. from the University of Connecticut School of Medicine.
Paul M. Finigan Executive Vice President and General Counsel
Mr. Finigan joined CuraGen with more than 20 years of legal and strategic experience and has served as Senior Vice President and General Counsel of the Company since August 2006. Prior to joining CuraGen, Mr. Finigan served as Corporate Counsel at 454 Life Sciences, Inc. Previously, he was a member of the Business Law Practice at Day, Berry & Howard, LLP, served as Chief Legal Officer and Strategic Advisor for Lumenos, Inc., a provider of consumer-driven health care programs, and prior to that was Senior Vice President and General Counsel at Value Health, Inc., a NYSE-listed provider of specialty managed care services and mail order prescription drugs. Mr. Finigan also held the position of Division Counsel at CIGNA Corporation and was Assistant General Counsel at U.S. Healthcare. Mr. Finigan is a member of the Board of Directors, Audit and Compensation Committees of Radnor Holdings Corporation, a leading manufacturer of food packaging and specialty chemical products. Mr. Finigan received a J.D. from Villanova University School of Law and a B.S. in economics from Villanova University.
Sean Cassidy Vice President and Chief Financial Officer
Mr. Cassidy served as Corporate Controller of 454 Life Sciences Corporation (454) since September 2002. Mr. Cassidy joined 454 when it was a development stage company and supported its growth into a successful commercial entity. During this time, Mr. Cassidy assisted 454 in a private round of financing in 2003, entering into a comprehensive License, Supply and Distribution Agreement with Roche Applied Science in 2005 and in the acquisition of 454 by Roche Applied Science in 2007. Prior to joining 454, Mr. Cassidy served as Manager of Financial Planning at CuraGen Corporation from August 2001 to September 2002. Mr. Cassidy also spent over eight years at Deloitte & Touche LLP's Hartford office in the audit practice. During this time Mr. Cassidy served both public and private companies in various industries; advising these clients on public and private securities offerings, mergers and acquisition due diligence reviews and annual and quarterly reporting requirements under the Securities and Exchange Commission's rules and regulations.
Mr. Cassidy earned both his Master of Business Administration degree and his Bachelor of Science in Accounting from the University of Connecticut in 2000 and 1992, respectively. Mr. Cassidy is a certified public accountant in the State of Connecticut.
Elizabeth Crowley Vice President of Development Operations
Cyrus Karkaria Ph.D. Vice President of BPS and Operations
Henri Lichenstein Ph.D. Vice President of Product Development
Hans Scholl Ph.D. Vice President of Regulatory Affairs and Quality Assurance
Ronit Simantov M.D. Vice President of Medical Development
